{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:37:43Z","timestamp":1793230663791,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mitsubishi"},{"name":"Janssen"},{"name":"GSK"},{"name":"Eli Lilly, Galapagos"},{"DOI":"10.13039\/100010795","name":"Chugai","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"crossref"}]},{"name":"BMS"},{"name":"AnaptysBio","id":[{"id":"https:\/\/ror.org\/01aaevk09","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1136\/ard-2023-224916","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T13:25:14Z","timestamp":1703078714000},"page":"409-416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3892-6947","authenticated-orcid":false,"given":"Kevin L","family":"Winthrop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kerschbaumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard E","family":"Voll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinand C","family":"Breedveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9469-946X","authenticated-orcid":false,"given":"Jacques-Eric","family":"Gottenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans P","family":"Kiener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2108-0030","authenticated-orcid":false,"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6103-7056","authenticated-orcid":false,"given":"John D","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8962-5642","authenticated-orcid":false,"given":"Maya H","family":"Buch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7881-2020","authenticated-orcid":false,"given":"Mary K","family":"Crow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8970-4260","authenticated-orcid":false,"given":"Jonathan","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6347-5738","authenticated-orcid":false,"given":"Leslie","family":"Crofford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6438-8663","authenticated-orcid":false,"given":"Ronald F","family":"van Vollenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9151-4650","authenticated-orcid":false,"given":"Caroline","family":"Ospelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1802-7311","authenticated-orcid":false,"given":"Stefan","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9294-2307","authenticated-orcid":false,"given":"Margreet","family":"Kloppenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain B","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7033-7520","authenticated-orcid":false,"given":"Tom WJ","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M","family":"Gravallese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-224916_bib1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq8476","article-title":"Oral mucosal breaks trigger anti-citrullinated bacterial and human protein antibody responses in rheumatoid arthritis","volume":"15","author":"Brewer","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1136\/ard-2023-224916_bib2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2022-eular.1693","article-title":"POS0531 abatacept delays the development of RA-clinical results after 18 momths from the randomized, placebo-controlled ARIAA study in RA-at risk patients","volume":"81","author":"Rech","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224916_bib3","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","article-title":"Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial","volume":"28","author":"Rivellese","year":"2022","journal-title":"Nat Med"},{"key":"10.1136\/ard-2023-224916_bib4","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41584-022-00845-w","article-title":"Precision medicine: the precision gap in rheumatic disease","volume":"18","author":"Lin","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2023-224916_bib5","article-title":"Cellular deconstruction of inflamed synovium defines diverse inflammatory phenotypes in rheumatoid arthritis","author":"Zhang","year":"2022","journal-title":"bioRxiv"},{"key":"10.1136\/ard-2023-224916_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.42347","article-title":"American college of rheumatology\/EULAR remission criteria for rheumatoid arthritis: 2022 revision","volume":"75","author":"Studenic","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224916_bib7","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41591-020-0939-8","article-title":"Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis","volume":"26","author":"Alivernini","year":"2020","journal-title":"Nat Med"},{"key":"10.1136\/ard-2023-224916_bib8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/1744666X.2023.2157814","article-title":"Inducibility or predestination? Queries and concepts around drug-free remission in rheumatoid arthritis","volume":"19","author":"D\u2019Onofrio","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1136\/ard-2023-224916_bib9","article-title":"Single-cell computational machine learning approaches to immune-mediated inflammatory disease: new tools uncover novel fibroblast and macrophage interactions driving pathogenesis","volume":"13","author":"Fritz","year":"2022","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2023-224916_bib10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41597-022-01264-y","article-title":"RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients","volume":"9","author":"Isaacs","year":"2022","journal-title":"Sci Data"},{"key":"10.1136\/ard-2023-224916_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-05044-4","article-title":"Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission","volume":"9","author":"Tasaki","year":"2018","journal-title":"Nat Commun"},{"key":"10.1136\/ard-2023-224916_bib12","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/ard-2022-223528","article-title":"Unmet need in rheumatology: reports from the advances in targeted therapies meeting, 2022","volume":"82","author":"Winthrop","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224916_bib13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41584-018-0006-8","article-title":"Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison","volume":"14","author":"Feld","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2023-224916_bib14","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211057975","article-title":"Axial involvement in psoriatic arthritis cohort (AXIS): the protocol of a joint project of the assessment of spondyloarthritis International society (ASAS) and the group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA)","volume":"13","author":"Poddubnyy","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1136\/ard-2023-224916_bib15","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224916_bib16","author":"Mease"},{"key":"10.1136\/ard-2023-224916_bib17","author":"Behrens"},{"key":"10.1136\/ard-2023-224916_bib18","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"Il17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2B study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-224916_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-224916_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-224916_bib21","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224916_bib22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of Ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224916_bib23","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3B trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-224916_bib24","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/keab119","article-title":"Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis","volume":"60","author":"Mease","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2023-224916_bib25","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/rheumatology\/keac500","article-title":"Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis","volume":"62","author":"Mease","year":"2023","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2023-224916_bib26","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2217\/cer-2018-0075","article-title":"Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics\/apremilast: a network meta-analysis","volume":"7","author":"McInnes","year":"2018","journal-title":"J Comp Eff Res"},{"key":"10.1136\/ard-2023-224916_bib27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.5152\/eurjrheum.2019.19057","article-title":"Comparative effectiveness of secukinumab and etanercept in biologic-na\u00efve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison","volume":"6","author":"Mease","year":"2019","journal-title":"Eur J Rheumatol"},{"key":"10.1136\/ard-2023-224916_bib28","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/nm.2854","article-title":"Primed for inflammation: enthesis-resident T cells","volume":"18","author":"Lories","year":"2012","journal-title":"Nat Med"},{"key":"10.1136\/ard-2023-224916_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224916_bib30","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224916_bib31","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/annrheumdis-2013-204963","article-title":"Sarilumab for the treatment of ankylosing spondylitis: results of a phase II, randomised, double-blind, placebo-controlled study (ALIGN)","volume":"74","author":"Sieper","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224916_bib32","author":"Research"},{"key":"10.1136\/ard-2023-224916_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152070","article-title":"FDA\/arthritis foundation osteoarthritis drug development workshop recap: assessment of long-term benefit","volume":"56","author":"Kim","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2023-224916_bib34","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2019.14735","article-title":"Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis: the FORWARD randomized clinical trial","volume":"322","author":"Hochberg","year":"2019","journal-title":"JAMA"},{"key":"10.1136\/ard-2023-224916_bib35","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.pain.2013.04.035","article-title":"A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee","volume":"154","author":"Spierings","year":"2013","journal-title":"Pain"},{"key":"10.1136\/ard-2023-224916_bib36","doi-asserted-by":"crossref","first-page":"509","DOI":"10.7326\/M20-0527","article-title":"Effects of Interleukin-1B inhibition on incident hip and knee replacement","volume":"173","author":"Schieker","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2023-224916_bib37","doi-asserted-by":"crossref","first-page":"f232","DOI":"10.1136\/bmj.f232","article-title":"Treatment for acute anterior cruciate ligament tear: five year outcome of randomised trial","volume":"346","author":"Frobell","year":"2013","journal-title":"BMJ"},{"key":"10.1136\/ard-2023-224916_bib38","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jpain.2022.08.010","article-title":"Optimizing and accelerating the development of precision pain treatments for chronic pain: IMMPACT review and recommendations","volume":"24","author":"Edwards","year":"2023","journal-title":"J Pain"},{"key":"10.1136\/ard-2023-224916_bib39","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/acr.24549","article-title":"Concept end points informing design considerations for confirmatory clinical trials in osteoarthritis","volume":"74","author":"Kim","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2023-224916_bib40","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1136\/ard-2023-224916_bib41","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/art.42023","article-title":"Urine proteomics and renal single-cell transcriptomics implicate interleukin-16 in lupus nephritis","volume":"74","author":"Fava","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224916_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000861","article-title":"Molecular endotypes of type 1 and type 2 SLE","volume":"10","author":"Robl","year":"2023","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2023-224916_bib43","article-title":"Mendelian randomization and pathway analysis demonstrate shared genetic associations between lupus and coronary artery disease","volume":"3","author":"Kain","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1136\/ard-2023-224916_bib44","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1177\/0961203320935976","article-title":"Characterization of type-I IFN subtype autoantibodies and activity in SLE serum and urine","volume":"29","author":"Harris","year":"2020","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-224916_bib45","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-224916_bib46","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224916_bib47","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-020-0901-9","article-title":"Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19","volume":"26","author":"Liao","year":"2020","journal-title":"Nat Med"},{"key":"10.1136\/ard-2023-224916_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000826","article-title":"Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features","volume":"5","author":"Hoffmann-Vold","year":"2019","journal-title":"RMD Open"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724000505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724000505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-224916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T01:01:20Z","timestamp":1736038880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724000505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0003496724000505"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-224916","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-224916","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 \u00a9 THE AUTHORS. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology, EULAR. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}